...
首页> 外文期刊>Circulation research: a journal of the American Heart Association >MicroRNAs for Restenosis and Thrombosis After Vascular Injury
【24h】

MicroRNAs for Restenosis and Thrombosis After Vascular Injury

机译:MicroRNA用于血管损伤后的再狭窄和血栓形成。

获取原文
获取原文并翻译 | 示例
           

摘要

Percutaneous revascularization revolutionized the therapy of patients with coronary artery disease. Despite continuous technical advances that substantially improved patients' outcome after percutaneous revascularization, some issues are still open. In particular, restenosis still represents a challenge, even though it was dramatically reduced with the advent of drug-eluting stents. At the same time, drug-eluting stent thrombosis emerged as a major concern because of incomplete or delayed re-endothelialization after vascular injury. The discovery of microRNAs revealed a previously unknown layer of regulation for several biological processes, increasing our knowledge on the biological mechanisms underlying restenosis and stent thrombosis, revealing novel promising targets for more efficient and selective therapies. The present review summarizes recent experimental and clinical evidence on the role of microRNAs after arterial injury, focusing on practical aspects of their potential therapeutic application for selective inhibition of smooth muscle cell proliferation, enhancement of endothelial regeneration, and inhibition of platelet activation after coronary interventions. Application of circulating microRNAs as potential biomarkers is also discussed.
机译:经皮血运重建彻底改变了冠心病患者的治疗方法。尽管持续的技术进步大大改善了经皮血运重建后患者的预后,但仍有一些问题尚待解决。特别是再狭窄仍然是一个挑战,尽管随着药物洗脱支架的出现大大减少了再狭窄。同时,由于血管损伤后再内皮的不完全或延迟,药物洗脱支架的血栓形成成为主要问题。 microRNA的发现揭示了以前未知的几个生物学过程的调控层,这增加了我们对再狭窄和支架血栓形成的生物学机制的了解,从而揭示了更有效和选择性治疗的有希望的新靶标。本综述总结了在动脉损伤后microRNA的作用的最新实验和临床证据,重点是其潜在治疗性应用的实用方面,以选择性抑制平滑肌细胞增殖,增强内皮再生和抑制冠状动脉介入治疗后的血小板活化。还讨论了循环microRNA作为潜在生物标志物的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号